(News Bulletin 247) – AstraZeneca announced this weekend that it had obtained “unprecedented” results in terms of survival in the treatment of early-stage lung cancer thanks to its Tagrisso tablet.
The biopharmaceutical group points out that 88% of patients with non-small cell lung cancer with EGFR mutation who participated in its phase III clinical trial ‘Adaura’ were still alive after five years.
According to the laboratory, Tagrisso thus reduced the risk of death by 51% compared to a placebo, both in the mainly targeted population, but also in the entire study population.
‘We think that these data presented during the ASCO should come to close the debate consisting in knowing if Tagrisso can yes or not be used as an adjuvant treatment’, react the analysts of UBS.
The trial involved patients with early-stage epidermal growth factor receptor (EGFR)-expressing non-small cell lung cancer after complete tumor surgery with curative intent.
Tagrisso, designed to inhibit EGFR mutations and with clinical activity against metastases, comes in 40 mg and 80 mg tablets to be taken orally once daily.
The drug has been approved in many countries as a first-line treatment for advanced EGFR-mutated lung cancer.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
